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Abstract Liver regeneration may take place after liver
injury through replication of hepatocytes or hepatic pro-
genitor cells called oval cells. Interferons (IFN) are natural
cytokines with pleiotrophic effects including antiviral and
antiproliferative actions. No data are yet available on the
physiology and cellular source of natural IFNs during liver
regeneration. To address this issue, we have analyzed the
levels and biologic activities of IFN-a/IFN-c in two models
of partial hepatectomy. After 2/3rd partial hepatectomy
(PH), hepatic levels of IFN-a and IFN-c declined transiently
in contrast to a transient increase of the IFN-c serum level.
After administration of 2-acetylaminofluorene and partial
hepatectomy (AAF/PH model), however, both IFN-a and
IFN-c expression were up-regulated in regenerating livers.
Again, the IFN-c serum level was transiently increased.
Whereas hepatic IFN-c was up-regulated early (day 1–5),
but not significantly, in the AAF/PH model, IFN-a was
significantly up-regulated at later time points in parallel to
the peak of oval cell proliferation (days 7–9). Biological
activity of IFN-a was shown by activation of IFN-a-specific
signal transduction and induction of IFN-a specific-gene
expression. We found a significant infiltration of the liver
with inflammatory monocyte-like mononuclear phagocytes
(MNP) concomitant to the frequency of oval cells. We
localized IFN-a production only in MNPs, but not in oval
cells. These events were not observed in normal liver
regeneration after standard PH. We conclude that IFN-c
functions as an acute-phase cytokine in both models of liver
regeneration and may constitute a systemic component of
liver regeneration. IFN-a was increased only in the AAF/PH
model, and was associated with proliferation of oval cells.
However, oval cells seem not to be the source of IFN-a.
Instead, inflammatory MNP infiltrating AAF/PH-treated
livers produce IFN-a. These inflammatory MNPs may be
involved in the regulation of the oval cell compartment
through local expression of cytokines, including IFN-a.
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Introduction
Liver regeneration is a unique biological process in which
partial organ loss can be compensated by a coordinated
proliferation of remaining viable liver cells. Normally,
hepatocytes are a quiescent cell population, but they may
proliferate under various pathophysiological conditions,
including viral or toxic hepatic injury or partial hepatec-
tomy (PH). However, if the capacity of hepatocytes to
replicate is severely impaired, liver tissue may still be
replaced by a facultative progenitor cell compartment
(‘‘oval cells’’). In rodents, proliferation of oval cells can be
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induced by exposure to hepatocarcinogens (e.g., 2-acetyl-
aminofluorene, AAF) and by subsequently submitting the
animals to proliferative stimuli, e.g., PH. Although this is
an alternative regeneration pathway when mature hepato-
cytes fail to replicate, there is now increasing evidence that
activation of these progenitor cells may also give rise to
hepatocellular carcinoma (HCC) (Dumble et al. 2002;
Braun et al. 1989).
The cell-signaling pathways that characterize alternative
regeneration pathways are mainly unknown (Batusic et al.
2005). In particular, very few factors have yet been identi-
fied that trigger oval cell-driven liver regeneration. Inter-
feron-gamma (IFN-c) was suggested as one of these factors
as its responsive gene program is activated in oval cell-
driven liver regeneration (Bisgaard et al. 1999). IFN-c was
shown to inhibit the proliferation of hepatocytes but to
promote the proliferation of oval cells (Brooling et al. 2005).
The oval cell response is attenuated in mice deficient in
IFN-c gene expression (Akhurst et al. 2005). As it has
been recently shown, its promotion of oval cells seems to be
rather indirect upon liver injury by stimulating inflammation
and aggravating liver damage (Knight et al. 2007).
Administration of IFN-a results in impaired rat liver
regeneration after PH by inhibition of hepatocyte replica-
tion and total protein synthesis (Theocharis et al. 1995;
Theocharis et al. 1997; Nishiguchi et al. 1986; Favre et al.
2001). When IFN-a is administered in rats after AAF/PH
treatment, the frequency of oval cells and the incidence of
HCCs are reduced (Nakaji et al. 2004; Alvarez et al. 2001).
Apparently, the absence of IFN-c or the addition of IFN-a/
-c have significant effects on liver regeneration. However, no
data are yet available on the physiology and cellular source of
natural IFNs during liver regeneration. To address this issue,
we have analyzed the levels and biological activities of
IFN-a/IFN-c in alternative regeneration pathways of the same
species. In particular, we aimed to delineate the effects of an
acute-phase reaction from that occurring as a result of either
proliferation of hepatocytes or oval cells.
Materials and methods
Animals
Male Wistar rats, purchased from Harlan–Winkelmann
(Germany), were allowed to acclimatize for 1 week prior to
the start of experiments, at which time they weighed between
180 and 220 g. Food and water were available ad libitum.
Treatment of animals
Rats were fed with 1.5 mg 2-acetylaminofuorene (AAF)
daily by intragastric administration, and partial
hepatectomy (PH) or sham operation (SO) was performed
on the 6th day. AAF was not given on the day of surgery.
PH was performed under ether anesthesia by midventral
laparotomy, ligation of the median anterior and left lateral
hepatic lobes separately with a silk suture, and complete
excision of ligated lobes. SO consisted of a midventral
laparotomy of similar extent, gentle manipulation of the
liver, followed by surgical closure of the abdominal wall
similar to PH-treated rats. AAF treatment was restarted on
the first postoperative day and continued for another 5 days
to a total dose of 15 mg per rat. Rats were killed on day 1,
3, 5, 7, 11 and 13 after PH or SO (three rats per time point).
A control group received only AAF without any operative
procedure (AAF controls, n = 3). Livers were snap frozen
in liquid nitrogen and stored at –80C.
Standard PH or SO was performed without AAF treat-
ment as described above. Since liver regeneration proceeds
faster without AAF treatment, earlier time points of up to
7 days were chosen (three rats per time point).
This study was approved by the Animal Ethics and
Research Committee of the University Medical Center
Go¨ttingen, and the experiments were conducted in accor-
dance with the laws and regulations of the state of Lower
Saxony, Germany.
Enzyme-linked immunosorbent assay
Liver samples were homogenized in ice-cold phosphate-
buffered saline (PBS), pH 7.8, containing 20 mmol/L
Hepes, 10 mmol/L KCl, 0.1 mmol/L ethylene-diamine-
tetraacetic acid (EDTA), 1 mmol/L dithiothreitol (DTT)
and 1 mmol/L phenylmethylsulfonyl fluoride (PMSF). We
used six volumes of lysis buffer for determination of IFN-a
in liver samples and eight volumes of buffer for determi-
nation of IFN-c. The homogenate was centrifuged for
30 min at 20,0009g at 4C, and the supernatant was used
in the enzyme-linked immunosorbent assay (ELISA)
according to the manufacturer’s instructions (Mouse IFN-a
ELISA Kit, Pestka Biomedical Laboratories, New Bruns-
wik, NJ, USA; Rat IFN-c ELISA Kit, BioSource Europe,
Nivelles, Belgium). Serum samples were analyzed undi-
luted according to the manufacturer’s protocol. The values
of the assays were determined in pg/mL serum or pg/g
frozen liver tissue, respectively.
RNA extraction, Northern blot hybridization
and real-time PCR
Total RNA was extracted from rat liver and from freshly
isolated and cultured cells according to Chirgwin et al.
(1979), separated on agarose gel by electrophoresis, blotted
onto nylon membranes and hybridized with a 32P-labeled
cDNA probe for rat Mx-2 (1.1 kb cDNA). Radiolabeled
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oligonucleotide specific for 28S ribosomal RNA was used
as a control.
For real-time PCR, 1 lg of total RNA was converted
into cDNA using Superscript II RT (Invitrogen, Carlsbad,
CA, USA) and oligo (dT)15 primer. The cDNA was
amplified with SYBR Green Master Mix (Applied Bio-
systems) according to the manufacturer’s instructions in an
ABI PRISM 7000 Sequence Detection System (Applied
Biosystems), and relative expression was calculated as
described elsewhere (Batusic et al. 2005). We used specific
primer pairs for rat IFN-a (TGCAACCCTCCTAGAC
TCATTCT/CCCCTACCTGCTGCATCAGA), IFN-c (GC
CCTCTCTGGCTGTTACTG/CCAAGAGGAGGCTCTTT




TGGCAGGGTTCTAAAATG), and ubiquitin c (CACCAAG
AAGGTCAAACAGGAA/AAGACACCTCCCCATCAA
ACC) as a housekeeping gene.
In situ hybridization
In situ hybridization experiments were performed accord-
ing to a protocol described by Braissant and Wahli (1998).
Antisense and sense IFN-a cDNAs were synthesized by a
standard PCR protocol (Invitrogen Platinum Taq) using a
cDNA template from a rat liver sample of acute liver injury
(24 h after CCl4 ingestion). The following primers con-
taining the T7 promoter were used: Antisense IFN-afor 50-
CGGCTCTGTGCTTTCTTGAT-30; Antisense IFN-aT7rev
50-TAATACGACTCACTATAGGG-AGTTGGCTGAGGA
AGACAGG-30; Sense IFN-aT7for 50-TAATACGACTC
ACTATAGGG-CGGCTCTGTGCTTTCTTGAT-30; Sense
IFN-a rev 50AGTTGGCTGAGGAAGACAGG-30. The
PCR products were purified by Qiagen Minielute Kit, and
antisense or sense riboprobes were synthesized using the
DIG labeling kit and T7 enzyme (Roche). Fixation,
hybridization and washing steps were performed on liver
sections of control rats and of AAF-treated rats at day 7
after PH, as described previously (Cimica et al. 2005).
Laser capture microdissection (LCM)
Frozen liver tissue specimens were cut as a series of 6 lm-
thick sections with a clean blade at -20C and mounted on
RNase-free slides. Sections were processed as described ear-
lier (Blaschke et al. 2003). Periportal and pericentral parts of
the hepatic lobule were separately collected by laser micro-
beam microdissection and captured by laser pressure cata-
pulting directly into the cap tubes. Three to five
microdissected periportal or pericentral zones were captured
on a single cap and RNA was extracted using the RNAqueous-
Micro RNA isolation kit (Ambion Europe, Huntingdon,
Cambridgeshire, UK) according to the manufacturer’s pro-
tocol. We synthesized cDNA using SuperScript II reverse
transcriptase (Invitrogen) and performed PCR with specific
primer pairs for rat IFN-a (50-CGGCTCTGTGCTTT
CTTGAT-30 and 50-TGCATCCCAAGCAGT–AGATG-30)
as described earlier (Batusic et al. 2004).
Immunohistochemistry
Immunohistochemical detection of proliferating cell
nuclear antigen (PCNA; Novocastra, UK) and CD68/
CD163 antigens (monoclonal anti CD68/clone ED1,
monoclonal anti CD163/clone ED2, both from Serotec,
UK) was performed by the immunoperoxidase method
according to a standard protocol (McCormick et al. 1993).
A polyclonal HRP-conjugated anti-mouse immunoglobulin
antibody (DAKO, P0161) was used in a second reagent
step. Alpha-fetoprotein (anti-AFP; DAKO) was detected by
the immunoperoxidase technique using the DAKO Envi-
sion system according to the manufacturer’s instructions
(DAKO, Glostrup, Denmark). Immunohistochemical
detection of natural killer (NK) cells in the rat liver was
performed by using the alkaline phosphatase-anti-alkaline
phosphatase (APAAP) method as described previously in
more detail (Batusic et al. 2005). We used a monoclonal
antibody against NKp30, an NK cell receptor that is
expressed in the majority of rat NK cells (clone CLH9;
dilution of primary antibody 1:100; Santa Cruz Biotech-
nology, Santa Cruz, CA, USA). Negative controls were
incubated with mouse IgM (DAKO, Denmark) instead of
primary antibodies.
Western blot analysis
Lysates were prepared by homogenization at 4C in
20 mM Tris–HCl (pH 8.0), 5 mM EDTA, 3 mM EGTA,
1 mM DTT, 1% SDS, 1 mM PMSF and protease inhibitor
cocktail (Sigma-Aldrich Inc., USA). Samples were cleared
by centrifugation at 15,0009g for 15 min at 4C, and the
protein concentration was measured by BCA assay (Pierce,
Rockford, IL, USA), using bovine serum albumin as
standard. Protein lysates were separated on SDS–poly-
acrylamide gels, electrotransferred to polyvinylidene
difluoride membranes (Invitrogen; USA) and probed with
primary antibodies overnight. The appropriate peroxidase-
conjugated secondary antibodies (DAKO, Glostrup,
Denmark) were then added in a dilution of 1:5,000 and
incubation continued for 1 h at room temperature. Bound
antibodies were visualized using chemiluminescent sub-
strate (ECL; AmershamPharmacia, UK). Equal loading
was previously controlled by transient Ponceau S staining.
The primary antibodies included: mouse monoclonal
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anti-Mx (mAB M143, 1:500, generous gift from Dr.
O. Haller, Freiburg, Germany), anti-JAK1 (Upstate Bio-
technology, USA), anti-Tyk2 (C-8; Santa Cruz, USA) and
anti-b-actin (clone AC-15, Sigma-Aldrich, USA).
Immunoprecipitation and SDS-PAGE analysis
Liver samples used for immunoprecipitation were lysed in
NP-40 lysis buffer containing 150 mM NaCl, 1% NP-40,
50 mM Tris–HCl (pH 8.0), 1 mM PMSF, 1 mM sodium
orthovanadate and an aliquot of protease inhibitor cocktail
(Sigma-Aldrich Inc., USA). After insoluble material was
removed by centrifugation, the lysates were incubated with
5 lg of antibody for 1 h at 4C. The following antibodies
were used (all from Upstate Biotechnology, USA):
anti-Stat1, anti-Stat2, anti-Stat3, and corresponding phos-
pho-specific antibodies. The formed antibody–antigen
complexes were precipitated using protein G Sepharose
beads (AmerhamPharmacia, UK) and washed several times
before being redissolved in 20 lL SDS-PAGE sample
buffer. Electrophoresis, transfer and immunoblotting were
carried out according to our protocols for Western blotting.
HepG2 cells treated with IFN-a (500 U/mL) were used as
positive controls after precipitation with Stat-1 or Stat-2.
Statistical analysis
The results are expressed as mean ± SEM. Significance in
differences was tested by Student’s t test, and p \ 0.05 was
considered significant.
Results
Two models of liver regeneration
To study hepatocyte-driven liver regeneration, we per-
formed PH or SO in rats without AAF treatment and
monitored weight and PCNA staining. Liver weight was
almost restored at day 7 after PH (90% ± 5%). PCNA
staining index already started to increase 8 h after PH
(2.5% positive nuclei/high power field vs. 0.4% in normal
liver), and reached a maximum of 24 h after PH (54%
positive nuclei/high power field). A second peak was
observed 72 h after PH (32% positive nuclei/high power
field) (Fig. 1a–d).
In AAF-treated rats, however, PCNA-positive nuclei
were not seen until day 3 after PH and were found exclu-
sively around portal tracts. A maximum of PCNA-positive
cells was observed at day 7 after PH (24 ± 7% positive
nuclei/HPF), all of which were identical or adjacent to
AFP-immunopositive cells (Fig. 1e–f).
Protein levels of IFN-a/-c in hepatocyte-driven liver
regeneration
IFN-a and IFN-c levels were measured in liver tissue samples
and in serum samples by ELISA. We found 81 ± 22 pg/g
IFN-a in homogenates of normal liver tissue. The IFN-a tissue
level did not differ significantly from the control value after
PH or SO (Fig. 2a). Serum levels of IFN-a were measured at
the lowest detectable range of 5–10 pg/mL and did not change
significantly above the lower detection range after standard
PH or SO (figure not shown).
Quantification of IFN-c in normal liver samples demon-
strated a concentration that is more than 100-fold above the
IFN-a concentration (10,143 pg/g liver). Immediately after
PH or SO, the IFN-c tissue level decreased to a minimum at
4 h (6,836 pg/g after PH, 6,993 pg/g after SO), followed by a
constant increase back to control level (Fig. 2b). In serum
samples, however, mean IFN-c concentration was up-regu-
lated from a normal level of 65.1 ± 15 pg/mL maximally to
343 ± 33 pg/mL in PH rats or to 226 ± 23 pg/mL in SO
rats at 8 h (*p = 0.036 between PH and SO rats) (Fig. 2c).
Expression of IFNs and IFN- inducible genes
in hepatocyte-driven liver regeneration
The expression IFN-inducible genes Mx-2, PKR, 2–5 OA
was detectable by both real-time PCR and Northern blot-
ting, but did not change significantly after standard PH or
SO (\2-fold variations; data not shown).
Protein levels of IFN-a/-c in oval cell-driven liver
regeneration
In AAF-treated rats, hepatic IFN-a concentration increased
significantly at day 7 after PH compared to sham-operated rats
(187.6 ± 16.5 pg/g in PH-group vs. 55.7 ± 12.2 pg/g in SO-
group; p = 0.0152). Maximal IFN-a concentration was
measured at day 9 after PH (213.2 ± 32 pg/g vs. 50 ± 7 pg/g
in SO-rats; p = 0.002). At days 11 and 13, the IFN-a con-
centration declined to levels slightly above the control level
(Fig. 3a). There was no difference in the IFN-a level between
normal control rats and AAF-fed controls (81.6 and 83 pg/g).
Serum levels of IFN-a were below the minimum threshold as
previously observed in non-AAF-treated rats.
IFN-c tissue concentration increased from a normal level
of 10,185 ± 155 pg/g to a maximum of 16,019 ± 1,102 pg/g
at day 3 in AAF/PH-treated rats (vs. 14,670 ± 880 pg/g in
AAF/SO-treated rats; p = 0.66). At day 7, the IFN-c level fell
to control level in PH- and SO-treated rats and remained at
control level until day 13 (10,398 ± 194 pg/g liver tissue in
PH rats) (Fig. 3b). Notably, the mean IFN-c tissue level was
higher in AAF-fed control rats than in normal controls
(12,891 ± 1,565 vs. 10,185 ± 155 pg/g; p = 0.22). In serum
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samples, IFN-c concentration gradually increased after PH
from normal level (67 ± 9 pg/mL) to a maximum at day 7
(310 ± 49 pg/ml AAF/PH vs. 189 ± 27 pg/mL AAF/SO,
p = 0.045). At day 9, serum IFN-c concentration fell to
control level. The mean IFN-c serum level was insignificantly
higher in AAF controls than in normal controls (82.4 ± 16 vs.
64 ± 9 pg/mL; p = 0.38) (Fig. 3c).
Expression of IFNs and IFN-inducible genes in oval
cell-driven liver regeneration
IFN-a mRNA levels were similar in normal livers and AAF
control-fed livers (± 0.04-fold). At day 3 after PH, IFN-a
gene expression was significantly up-regulated (1.86-fold
vs. 0.72-fold in SO-rats; p = 0.02). A maximal increase of
IFN-a transcripts was found at day 7 (2.52-fold in PH rats
vs. 0.75-fold in SO-rats; p = 0.037). At day 9 after PH,
IFN-a gene expression was still significantly increased
above control or SO level (2.28-fold vs. 1.21-fold;
p = 0.02). At day 13 after PH, IFN-a mRNA fell to control
or sham level, again. (Fig. 4a).
Hepatic IFN-c gene expression was up-regulated by
1.5-fold with AAF treatment alone (AAF controls compared
to normal controls). At days 1 and 3 after PH, we found more
IFN-c transcripts (2.42-fold and 2.83-fold vs. normal liver).
However, up-regulation of IFN-c mRNAs was also found
after SO (1.9-fold and 2.2-fold, respectively). Hence, the
difference was not significant between PH- and SO-treated
Fig. 1 Normal liver regeneration (a–d) and regeneration via oval
cells (e–f). (a–d) PCNA staining of liver sections from normal rats at
(a), 8 h (b), 24 h (c) and 72 h (d) after standard PH in rats.
(e–f) Serial sections (5 lm) of AAF-treated rats at 7 days after PH
demonstrating co-localization of PCNA (e) and AFP (f)-positive cells.
Scale bar = 100 lm (applies to a–f)
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rats (p = 0.23 at day 1 and p = 0.25 at day 3). At day 5 after
PH or SO, the level of IFN-c mRNA returned to normal and
remained at control level (±0.5-fold) until day 13 (Fig. 4b).
We used AFP mRNA as a marker for the presence of
oval cells. Cyclin D1 was used as a marker of proliferation
of liver cells including oval cells. Both AFP and cyclin-D1
gene expression were up-regulated starting at day 1 and
reached a 210-fold (AFP) or 52-fold (Cyclin-D1) maxi-
mum at day 7 after PH. While AFP gene expression was
quickly down-regulated, the expression of cyclin-D1 was
still significantly above control level until day 11 (24-fold
compared to normal liver) (Fig. 4c, d).
Biological activity of IFN-a was studied by expression
of the Mx-2 gene, which is exclusively inducible by IFN-a
but not IFN-c. With real-time PCR, Mx-2 mRNA was up-
regulated starting at day 3 after PH, and reached a transient
12-fold increase at day 7 after PH (vs. 1.04-fold after SO).
The Mx-2 mRNA level fell rapidly at days 9 and 11
(3.6- and 2.2-fold after PH vs. 1.4- and 1.54-fold after SO)
(Fig. 4e). Using Northern blot hybridization, Mx-2 tran-
scripts were hardly detectable in normal rats. The Mx-2
hybridization signal increased at day 3 after PH and
showed a marked transient overexpression at day 7 after
PH before declining rapidly to control levels (Fig. 4f).
Next, we examined Mx-2 protein by Western blotting
which showed an increase starting at day 3 and culminated
with a strong peak at day 9 after PH (Fig. 4f).
Activation of the IFN-a signal transduction pathway
in AAF/PH-treated rat livers
We evaluated the activation of the downstream effectors in
the Jak/Stat transduction pathway. Western blot analysis of
liver tissue extracts showed an up-regulation of the IFN-a
receptor-associated kinases Jak-1 and Tyk-2 in AAF/PH-
treated rats (Fig. 5a). Day 3 was the first time point after
PH that both kinases were up-regulated altogether.
In response to ligand-dependent IFN-a receptor activa-
tion, latent cytoplasmic Stat-1, Stat-2 and Stat-3 transcrip-
tion factors are activated via phosphorylation on tyrosine
residues. We immunoprecipitated Stat-1, Stat-2 and Stat-3
from tissue homogenates and subsequently immunoblotted
the immunoprecipitates with phospho-specific Stat anti-
bodies. In normal resting livers, Stat-1 activation was not
detected but Stat-2 and Stat- 3 activation was found at low
levels (Fig. 5b). In AAF-fed control livers, Stat-1 was
activated at low levels similar to the ones found for phos-
phorylated Stat-2 and Stat-3. In AAF/PH-treated animals,
we found an enhanced activation of Stat-1, Stat-2 and Stat-3
starting at day 1 after PH. Stat-1 was maximally activated at
days 3–7, Stat-2 similarly between days 1 and 11, whereas
phosphorylated Stat-3 was maximally detected at day 7
(Fig. 5b).


































































Fig. 2 Tissue and serum concentration of IFN-a and IFN-c after
standard PH or SO (sham operation). Protein levels were determined
in liver tissue homogenates (a, b) and serum samples (c) from three
rats for each time point. Values are averages ± SEM. IFN-a was not
measurable in serum samples
136 Histochem Cell Biol (2011) 136:131–144
123
To detect whether Stat-3 interacts with corresponding
Stat-proteins, we immunoprecipitated proteins with an
antibody directed to Stat-1, and detected Stat-3 at days of
Stat-1 activation (days 3, 7 and 11; Fig. 5c). As shown in
Fig. 5b, Stat-2 was activated from day 1 up to day 11 after
PH. Interestingly, Stat-3 co-immunoprecipitated with Stat-
2 at days 1 and 11 only (Fig. 5c).
IFN-a expression in the periportal zone
of AAF/PH-treated rat livers
To localize IFN-a synthesis, we performed in situ hybrid-
ization and LCM of AAF-treated rat livers. In normal
untreated livers and AAF-fed control livers, hybridization
signals for IFN-a were not detectable. Hybridization sig-
nals for IFN-a were increasingly detectable from day 3 up
to day 7 after PH, and decreased thereafter. Hybridization
signals for IFN-a were almost exclusively found in the
periportal zone, thus labeling a large proportion of the
periportal cellular reaction at day 7 (Fig. 6a, b).
Next, we microdissected liver cells by laser capture
around portal tracts (zone 1) and central veins (zone 3) at
day 7 after PH/AAF treatment and looked for IFN-a tran-
scripts by RT-PCR analysis (Fig. 6c, d). According to the
results above, we found IFN-a transcripts in the portal area,
but not centrally within the liver lobule (zone 3) (Fig. 6e).
Detection of mononuclear phagocytes (MNP)
and natural killer (NK) cells
MNP are known to be a principal source of IFN-a. To
check for MNP in AAF/PH-treated livers, we performed
immunohistochemical staining with the monoclonal anti-
bodies ED1 and ED2 in serial sections already used for in
situ hybridization or LCM. The antigen recognized by ED1
is the rat homolog of human CD68, and the antigen rec-
ognized by ED2 is the rat CD163 cell surface glycoprotein.
Cells positive for ED1 and ED2 were found along the
sinusoids, in accordance with the assumption that mono-
nuclear phagocytes (ED1 positivity) resident in the normal
liver are mainly mature tissue macrophages (ED2 positiv-
ity) (Fig. 7a, b). In rats treated by PH/AAF administration,
ED1? cells were increasingly found within the periportal
cellular reaction containing AFP? cells. ED1? cells were
found adjacent to AFP? cells and their numbers increased
in parallel. The periportal ED1? cells were mainly ED2-,
hence representing inflammatory cells (Fig. 7c–f).
NK cells are also known to reside in the liver and are
capable of producing significant amounts of IFN-c and
minor amounts of IFN-a (Ahmad and Alvarez 2001). To
determine whether NK cells may also be up-regulated in
the setting of AAF/PH treatment, we performed APAAP
immunostaining for the ubiquitous NK cell receptor
NKp30, which plays a prominent role in NK cell activa-
tion. In contrast to ED1 immunostaining, we could not
detect a significant influx or up-regulation of NKp30-
positive cells. NKp30-immunopositive cells were not
detectable in normal or AAF-fed control rats (Fig. 7g). We
found single NKp30-positive cells at days 7 and 11. Within
one enlarged portal field only, a maximum of three im-
munopositive (red) cells were found at day 11 after PH
(Fig. 7h). Real-time PCR of the mRNA encoding the
NKp30 cell receptor did not show any significant variation
in AAF/PH-treated rats (data not shown). The amount of
NKp30 mRNA at day 11 after PH was 1.4-fold compared
to normal liver.
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Fig. 3 Tissue and serum concentration of IFN-a and IFN-c in AAF-
treated rats after PH or SO (sham operation): ELISAs of liver tissue
homogenates (a, b) and serum samples (c). Average protein levels
were determined from three rats for each time point (±SEM). IFN-a
concentration was not measurable in serum samples
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We studied total protein content by Western blotting
and found increased amounts of ED1 antigens starting at
day 1 after PH. Maximal levels were found at day 9 after
PH (Fig. 7i). Western blots for Nkp30 showed constant
levels without significant changes, thus confirming our
previous immunohistochemical and PCR results (not
shown).
Discussion
IFNs are a family of related cytokines that mediate a
range of diverse functions including immunomodulatory
and antiproliferative activities. All subtypes of IFNs elicit
their cellular effects through the transcriptional activation
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Fig. 4 Gene expression of IFN-a/-c, alpha-fetoprotein (AFP), Cyclin
D1, and IFN-a-inducible Mx-2 gene in the AAF/PH model of liver
regeneration. Relative gene expression measured by real-time PCR
of IFN-a mRNA (a), IFN-c mRNA (b), AFP (c), Cyclin D1 (d),
and Mx-2 (e). Mean ± SEM; normal control livers were set as 1.
(f) Representative Northern blot (NB) and Western blot (WB)
hybridization for Mx-2 in normal rats (N), AAF-fed control rats (N#),
and AAF-treated rats up to 13 days after 2/3 PH. Total RNA was
hybridized with a 32P-labeled probe for Mx-2. Loading controls
were performed with an oligonucleotide probe for ribosomal 28S or
anti-b-actin antibody, respectively
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activator of transcription) proteins. Type I (a and b) and
type II (c) IFN signal through distinct receptors but
related Jak-Stat pathways (Heim 2000). Different
combinations of these Stats result in different transcrip-
tion factor complexes and binding to two different
classes of response elements (Kalvakolanu 2003). In
most cell lines, activation of the IFN-c receptor leads to
phosphorylation of Stat-1 only, followed by nuclear
translocation of Stat-1 homodimers and binding to
gamma-activated sequence (GAS) response elements of
IFN-inducible genes.
On the other hand, the activation of the IFN-a-specific
receptor induces the activation of Stat-1, Stat-2 and Stat-
3, all of which may activate GAS response elements
once they have combined with different combinations
of dimers. IFN-a-specific gene expression may ensue
when Stat-1 and Stat-2 form heterodimers, which in
combination with interferon-regulatory factor 9 (IRF-9)
can bind to interferon-stimulated response elements
(ISRE) in the promoters of IFN-a target genes (Ozato
et al. 2007).
Compared to IFN-c, Type I IFNs have more potent
antiviral, antiproliferative and antitumoral properties.
Hence, IFN-a is currently the most frequently used
cytokine in the treatment neoplastic diseases or viral
hepatitis (Brassard et al. 2002). It is now well under-
stood that its additional capacity to activate ISRE har-
boring genes accounts best for its unique actions (Heim
2000). Among these ISRE-harboring genes, the Mx
gene family is exceptional because it is activated in
vivo almost exclusively by IFN-a, but not IFN-c. Thus,
Mx gene products were used as surrogate markers for
the biological activity of IFN-a in humans and rodents
(Staeheli et al. 1986; von Wussow et al. 1990; Meier
et al. 1990).
We found increased IFN-c serum levels after PH
in both models of regeneration. Serum concentration of
IFN-a remained so low that it was not measurable.
Comparing liver tissue levels of IFN-a/-c after standard
PH or SO, we did not find any significant changes or any
activation of corresponding signaling pathways. However,
hepatic levels of IFN-a and IFN-c were up-regulated in
AAF/PH-treated livers. Whereas IFN-c was up-regulated
at early time points, up-regulation of IFN-a and activation
of IFN-a signaling occurred at later time points simulta-
neously with the peak of oval cell proliferation. In parallel,
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Fig. 5 Activation of the Jak/Stat-signal transduction pathway in the
AAF/PH-rat model. a Protein expression of Jak-1, Tyk-2 and b-actin
(control) were examined by Western blot analysis using rabbit anti-
Jak-1 polyclonal Ab, mouse anti-Tyk-2 mAb and mouse anti-b-actin
mAb. b Immunoprecipitations of whole liver tissue homogenates
were performed with antibodies to Stat-1, Stat-2 and Stat-3. Tyrosine
phosphorylation status of these proteins was then evaluated by
immunoblotting using phospho-specific antibodies (upper band).
Blots were subsequently stripped and reprobed with the primary anti-
Stat antibody (lower band) to control the amount of immunoprecip-
itated protein. c Co-immunoprecipitation of Stat-3 with Stat-1 and
Stat-2 proteins in the AAF/PH-rat model. N, normal controls; N#,
AAF-fed control animals
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we found increasing numbers of IFN-expressing, mono-
cyte-like mononuclear phagocytes (MNP) in regenerating
livers of AAF/PH-treated rats.
The tyrosine kinase 2 (Tyk-2) is associated with the
IFN-a receptor, but not with the IFN-c receptor. On protein
level, we found a constitutive up-regulation of Tyk-2
starting already at day 1 after PH. Stat-1, Stat-2 and Stat-3
were activated starting at day 1 in AAF/PH-treated rats.
Stat-1 and Stat-2 phosphorylation was similarly up-regu-
lated at days 1 and 3 after PH, whereas Stat-3 activation
occurred later at day 7 after PH.






d 7 d 7
Fig. 6 Localization of IFN-a synthesis: (a–b) In situ hybridization
with an IFN-a-specific probe on sections of AAF-treated livers. IFN-
a-specific cDNA was transcribed into DIG-labeled antisense (a) or
sense (b) RNA probes and hybridized with sections of livers at day 7
after PH; magnification 9100. (c–e) Laser capture microdissection
(LCM) and subsequent RT-PCR analysis of IFN-a mRNA.
Representative portal field of a regenerating liver at day 7 after PH/
AAF treatment before (c) and after LCM (d). Total RNA was
extracted from the LCM sample and subsequently analyzed by RT-
PCR for IFN-a transcripts (e). PF, periportal area (zone I); CV,
pericentral area (zone III); H2O negative control
Fig. 7 Detection of mononuclear phagocytes (MNP) by POD in AAF/
PH-treated rats. Normal livers (a–b): ED1-positive cells (arrowheads)
are dispersed throughout the entire parenchyma and the portal tracts of
normal livers (a), whereas ED-2-positive cells (short arrows) were
mainly found within the parenchyma but not in the portal tracts (b).
AAF/PH-treated rats (c–f): ED1-positive cells within periportal clusters
of day 3 (c), day 7 (d, e) and day 13 after PH (f). NK cells were detected
in serial sections by APAAP staining for the NKp30 cell receptor. g No
NKp30-positive cells were detectable in AAF-fed control rats. h Max-
imum numbers at day 11 after PH (long arrows). Magnification 9100
(a–d), 9200 (e–g), 9400 (h). i Representative Western blot of ED1
protein expression in liver homogenates up to 13 days after AAF/PH
treatment (N, normal rat liver; N#, AAF-fed control rat liver). b-actin
expression was used as a loading control
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In the liver, Stat-1 is mainly activated by IFN-a and IFN-c
and its activation is correlated positively with liver injury,
but negatively with hepatocyte proliferation or liver regen-
eration (Gao 2005; Sun et al. 2006). Activation of Stat-1 or
Stat-3 plays an essential role in the antiviral and antitumor
activity of IFN-a (Meraz et al. 1996; Zhu et al. 2004).
Stat-2 is known to be activated only by Type I IFN
(IFN-a/IFN-b), but not by IFN-c or any other cytokines
(Heim 2000; Gao 2005). STAT2-deficient mice have an
increased susceptibility to viral infection and the loss of a
Type I IFN autocrine/paracrine loop (Park et al. 2000). Its
activation is a key signal involved in the antiviral therapy
of IFN-a in viral hepatitis patients (Radaeva et al. 2002;
Nguyen and Gao 2002).
Stat-3 was shown to be activated in hepatocytes after
standard PH (Cressman et al. 1995) and in mature oval
cells differentiating along the hepatocyte lineage (Sanchez
et al. 2004). Stat-3 can be activated by a variety of cyto-
kines, including interleukin-6, OncostatinM, leukemia
inhibiting factor, epidermal growth factor, platelet-derived
growth factor, G-CSF, leptin and IFN-a, but not by IFN-c
(Akira 2000; Waelput et al. 2000; Heim 2000; Yang et al.
1998). In models of liver regeneration, IL-6 seems to be by
far the most relevant pathway for Stat-3 activation
(Cressman et al. 1996). Interaction of IL-6 with its receptor
induces the activation of cytoplasmic Stat-3, but not Stat-1
or Stat-2. Activated Stat-3 then translocates to the nucleus
to induce the transcription of many target genes, including
acute-phase genes, but not antiviral genes such as Mx
(Akira 1997). Several studies have demonstrated an
important role of the IL-6/Stat-3 pathway in hepatopro-
tection, liver development and normal liver regeneration
after standard PH (Wuestefeld et al. 2003; Streetz et al.
2003). Stat-3 signaling may be also necessary for oval cell-
mediated liver regeneration since levels of IL-6 are ele-
vated in corresponding mice models, and IL-6-mediated
hyperactive Stat-3 signaling results in enhanced oval cell
numbers (Yeoh et al. 2007; Matthews et al. 2004).
We found a constitutive activation of Stat-3 in normal
rats and maximal Stat-3 phosphorylation at day 7 after PH
when maximal AFP/PCNA immunopositivity occurred.
Co-immunoprecipitation studies showed that maximal Stat-
3 activation is not associated with Stat-2 activation, indi-
cating that other cytokines besides IFN-a may cause Stat-3
activation during oval cell-driven liver regeneration.
Notably, Stat-1 and Stat-2 were activated earlier than
Stat-3. Similar to the increase of the IFN-c level in AAF/
PH-treated rats, Stat-1 was already activated at days 1 and
3 after PH, before maximal oval cell numbers occurred.
Tyk-2 and Stat-2 are two members of the IFN-a signaling
pathway: the expression and activation of both were
simultaneously up-regulated from day 1 up to 11 of the
AAF/PH-protocol.
NK cells are important effector cells of innate immunity
known to produce large amounts of IFN-c and eventually
IFN-a, once activated (Ahmad and Alvarez 2001). Sun and
Gao have shown that hepatic NK cells are increased in
numbers after PH and highly activated by demonstrating
IFN-c production in hepatic NK cells (Sun and Gao 2004).
We studied the presence of activated NK cells in oval cell-
mediated liver regeneration by identification of the ubiq-
uitous NKp30 receptor (Pende et al. 1999). We could not
detect NKp30-positive cells in normal rats or before 7 days
after PH. Thereafter, single NKp30-positive cells were
detectable interspersed in the periportal cellular reaction.
Since we could not measure an increased IFN-c or NKp30
level in liver tissue at days 7 or later, we suggest that the
low numbers of NKp30-positive NK cells do not signifi-
cantly affect IFN-c or IFN-a tissue levels.
MNP are known to be recruited and activated by IFN-c
in models of chemical-induced hepatocarcinogenesis
(Matsuda et al. 2005). The MNP system is characterized by
the expression of ED1 or ED2 antigens (Dijkstra et al.
1985). No other cell types except MNP are positive for any
ED-monoclonal antibody. ED1 recognizes a cytoplasmic
antigen (CD68) present in monocytes and in most macro-
phages, whereas ED-2 recognizes a membrane antigen
(CD163) of tissue macrophages only (e.g., Kupffer cells of
the liver) (Armbrust and Ramadori 1995). Several studies
have revealed not only morphological but also functional
differences between monocytes and resident tissue mac-
rophages (Armbrust et al. 1997, Armbrust et al. 1993). We
could show in a previous work that small ED1?/ED2-
monocyte-like MNPs constitutively express IFN-a and that
Mx-2 is constitutively expressed in those monocyte-like
MNPs, but not in resident ED1?/ED2? macrophages
(Kupffer cells) (Batusic et al. 2004). In this paper, we
demonstrate an up-regulation of Mx-2 at RNA and protein
levels in the AAF/PH model. In parallel, the number of
monocyte-like ED1?/ED2- MNPs was increased. In par-
ticular, ED1? MNPs were found adjacent to AFP?/PCNA?
cells of the periportal zone. Using in situ hybridization and
LCM, we found increased IFN-a expression in periportal
zones of AAF/PH-treated rats, but not in the pericentral
zone consisting mainly of resting hepatocytes. We postu-
late that the up-regulation of IFN-a and Mx expression
might be a direct effect of the influx of monocyte-like MNP
during the proliferation of the oval cells.
IFN-c levels were not significantly different between PH
and SO rats in both regeneration models except for a
transient increase in serum. Treatment with AAF alone
tended to increase IFN-c in serum and tissues, without any
operation. Therefore, we conclude that IFN-c behaves as an
acute-phase cytokine in both models of liver regeneration,
probably promoting the recruitment/activation of MNP into
the liver. The IFN-c level of PH- or sham-operated rats
142 Histochem Cell Biol (2011) 136:131–144
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differed significantly only in serum, indicating additional
extrahepatic IFN-c production. The increased activity of
IFN-a in oval cell-driven liver regeneration might be an
effect of an influx of monocyte-like MNP, but not NK
cells. Those inflammatory MNPs may regulate the prolif-
eration of oval cells through local expression of cytokines
including IFN-a.
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